Success Stories

Event Videos

Maternal-fetal transmission of hepatitis C infection: what is so special about babies? http://www.ncbi.nlm.nih.gov/pubmed/24345835 Wen JW, Haber BA. Maternal-fetal transmission of hepatitis C infection: what is so special about babies? J PediatrGastroenterolNutr. 2014; 58(3): 278-82. Published on: Mar-2014 Read more	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir http://www.ncbi.nlm.nih.gov/pubmed/24123097 Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology. 2014; 59(3): 986-95. Abstract Published on: Mar-2014 Read more
Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment http://www.ncbi.nlm.nih.gov/pubmed/24372662 Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J GastroenterolHepatol. 2014; 29(3): 428-34. Abstract Published on: Mar-2014 Read more	Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis http://www.ncbi.nlm.nih.gov/pubmed/23775519 Bardou-Jacquet E, Philip J, Lorho R, Ropert M, Latournerie M, Houssel-Debry P,Guyader D, Loréal O, Boudjema K, Brissot P. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFEhemochromatosis. Hepatology. 2014;59(3):839-47. Abstract Published on: Mar-2014 Read more
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy http://www.ncbi.nlm.nih.gov/pubmed/23847109 Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS Jr, Alexeeva O, Zupanets IA, Grinevich V, Baranovsky A, Dudar L, Fadieienko G, Kharchenko N, Klaryts'ka I, Morozov V, Grewal P, McCashland T, Reddy KG, Reddy KR, Syplyviy V, Bass NM, Dickinson K, Norris C, Coakley D, Mokhtarani M, Scharschmidt BF; HALT-HE Study Group. Randomized, double-blind, controlled study of glycerol phenylbutyrate inhepatic encephalopathy. Hepatology. 2014; 59(3):1073-83. Abstract Published on: Mar-2014 Read more	Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality http://www.ncbi.nlm.nih.gov/pubmed/23676440 Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Treatment of patients withdual hepatitis C and B by peginterferon α and ribavirin reduced risk ofhepatocellular carcinoma and mortality. Gut. 2014;63(3):506-14. Abstract OBJECTIVE: Whether peginterferon α and ribavirin combination therapy reduces risk of hepatocellular carcinoma (HCC) or improves survival in patients dual-infected with hepatitis C virus (HCV) and hepatitis B virus (HBV) is unknown. Since it is ethically impossible to conduct a randomised trial to learn the long-term efficacy, we rely upon the large database to explore the effectiveness of combination therapy among dual-infected patients. DESIGN: Published on: Mar-2014 Read more
Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients http://www.ncbi.nlm.nih.gov/pubmed/24115225 Buck M, Garcia-Tsao G, Groszmann RJ, Stalling C, Grace ND, Burroughs AK, Patch D, Matloff DS, Clopton P, Chojkier M. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology. 2014; 59(3): 1052-9. Abstract Published on: Mar-2014 Read more	Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with Chronic Hepatitis C http://www.ncbi.nlm.nih.gov/pubmed/24316262 Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L,Brown RS Jr, Hézode C, Rizzetto M, Paraná R, De Meyer S, De Masi R, Luo D,Bertelsen K, Witek J. Telaprevir twice daily is noninferior to telaprevir every 8hours for patients with chronic hepatitis C. Gastroenterology. 2014Mar;146(3): 744-753. Abstract BACKGROUND & AIMS: We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. METHODS: Published on: Mar-2014 Read more
Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites: a diagnostic accuracy study http://www.ncbi.nlm.nih.gov/pubmed/23907731 Farias AQ, Silvestre OM, Garcia-Tsao G, da Costa Seguro LF, de Campos Mazo DF, Bacal F, Andrade JL, Gonçalves LL, Strunz C, Ramos DS, Polli D, Pugliese V, Rodrigues AC, Furtado MS, Carrilho FJ, D'Albuquerque LA. Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites: a diagnostic accuracy study. Hepatology. 2014; 59(3): 1043-51. Abstract Published on: Mar-2014 Read more	The contribution of viral hepatitis to the burden of chronic liver disease in the United States http://www.ncbi.nlm.nih.gov/pubmed/24445570 Roberts HW, Utuama OA, Klevens M, Teshale E, Hughes E, Jiles R. Thecontribution of viral hepatitis to the burden of chronic liver disease in theUnited States. Am J Gastroenterol. 2014;109(3):387-93. Abstract OBJECTIVES: Chronic liver disease (CLD) is increasingly recognized as a major public health problem. However, in the United States, there are few nationally representative data on the contribution of viral hepatitis as an etiology of CLD. METHODS: Published on: Mar-2014 Read more

CLF Intro movie

SMS requests to

9224791366

Ask The Expert

Pediatric Liver Specialists in India

Centres offering Genetic Testing for Pediatric Liver Diseases

Financial Aid Offered by Trusts

Follow us on:

Facebook Twitter YouTube